About

Partners

Axis Therapeutics is a joint venture established in 2018 between Athenex, Inc. (NASDAQ:ATNX) and Xiangxue Life Sciences Limited, a subsidiary of Xiangxue Pharmaceutical Co., Ltd (Shenzhen Exchange:300147).

Axis Therapeutics in-licensed the worldwide rights (excluding mainland China) for the research, development and commercialization of T cell receptor-engineered T cells (TCR-T), a technology based on the TAEST (TCR Affinity Enhanced Specific T cell therapy) platform from Xiangxue Life Sciences.  Xiangxue Life Sciences retains the rights to mainland China for the technology.

About

Get in touch with us

Science

News

Contact

logo-white.png

About

© Copyright Axis Therapeutics 2020. All Rights Reserved.